Paramita Chatterjee
Paramita is an editor on the DealStreetAsia desk. A former business reporter, she has covered mergers and acquisitions, private equity and venture capital for leading publications in India, and often dons that hat in her current role as well. She enjoys playing the sitar.
Stories by Paramita Chatterjee
Beyond the Buyout: What’s working for private credit in Asia?
This edition looks at the rise and diversification of the private credit asset class.
Healthcare-focused Indian PE firm Somerset Indus exits Hexagon Nutrition
With this deal, Somerset has cashed out from most of its investments from the first fund.
India: Spyne raises $16m in Series A round from Vertex Ventures, others
Existing investors Accel, Storm Ventures, and Alteria Capital joined the round.
ASG in talks to buy stake in India’s Bavishi Eye Hospitals
ASG had raised $188m from General Atlantic and Kedaara in 2022.
Indian eyewear retailer Lenskart eyes IPO at $10b valuation: Report
The company last raised $200m in a secondary round at a $5b valuation in June 2024.
India: Mid-market PE firm Carpediem Capital eyes $50m continuation fund
Multiples, India Quotient, and Lightbox are also raising continuation vehicles.
Navi appoints new CEOs, Sachin Bansal to continue as executive chairman
Rajiv Naresh will take over as Navi Technologies CEO; Abhishek Dwivedi will be CEO of Navi Finserv.
Why are Indian GPs hooked to continuation funds?
ChrysCapital, Anicut Capital, and Sauce.VC floated continuation funds last year.
Beyond the Buyout: Will KWAP’s partnerships with global GPs spur Malaysia investments?
Also in this edition: Impact of India’s Budget on the private capital
Ranjan Pai’s family office Claypond in talks to buy stake in Panacea Medical
Panacea makes medical equipment focused on cancer care.
